COMPARISON OF OBESITY DIAGNOSTIC METHODS IN CHRONIC HEMODIALYSIS PATIENTS

2021 ◽  
Vol 2 (1) ◽  
pp. 60-65
Author(s):  
Filinjuk P.Ju.
Keyword(s):  
Renal Failure ◽  
Sensitivity And Specificity ◽  
Hemodialysis Patients ◽  
Chronic Hemodialysis ◽  
Diagnostic Methods ◽  
Dialysis Patients ◽  
End Stage Renal Failure ◽  
Treat Ment ◽  
End Stage ◽  
Bioimpedance Measurement

The article deals with the problem of diagnosing obesity in patients with end-stage renal failure receiving treat-ment with programmed hemodialysis. The aim of the work was to study the indicators of the information content of various methods for diagnosing obesity among dialysis patients. The objective of the study was to compare the sensitivity and specificity of such methods for diagnosing obesity as BMI, OT / OB index, BAI, electronic caliperom-etry, bioimpedance measurement. The possibility of prac-tical application of the study is to optimize the approach to methods of diagnosing obesity in dialysis patients.

scholarly journals Aluminum, Iron, Lead, Cadmium, Copper, Zinc, Chromium, Magnesium, Strontium, and Calcium Content in Bone of End-Stage Renal Failure Patients

1999 ◽  
Vol 45 (9) ◽  
pp. 1548-1556 ◽  
Author(s):  
Patrick C D’Haese ◽  
Marie-Madeleine Couttenye ◽  
Ludwig V Lamberts ◽  
Monique M Elseviers ◽  
William G Goodman ◽  
...  
Keyword(s):  
Renal Failure ◽  
Trace Elements ◽  
Trace Metals ◽  
Trace Metal ◽  
Renal Osteodystrophy ◽  
Dialysis Patients ◽  
End Stage Renal Failure ◽  
Metal Contents ◽  
Bone Biopsies ◽  
End Stage

Abstract Background: Little is known about trace metal alterations in the bones of dialysis patients or whether particular types of renal osteodystrophy are associated with either increased or decreased skeletal concentrations of trace elements. Because these patients are at risk for alterations of trace elements as well as for morbidity from skeletal disorders, we measured trace elements in bone of patients with end-stage renal disease. Methods: We analyzed bone biopsies of 100 end-stage renal failure patients enrolled in a hemodialysis program. The trace metal contents of bone biopsies with histological features of either osteomalacia, adynamic bone disease, mixed lesion, normal histology, or hyperparathyroidism were compared with each other and with the trace metal contents of bone of subjects with normal renal function. Trace metals were measured by atomic absorption spectrometry. Results: The concentrations of aluminum, chromium, and cadmium were increased in bone of end-stage renal failure patients. Comparing the trace metal/calcium ratio, significantly higher values were found for the bone chromium/calcium, aluminum/calcium, zinc/calcium, magnesium/calcium, and strontium/calcium ratios. Among types of renal osteodystrophy, increased bone aluminum, lead, and strontium concentrations and strontium/calcium and aluminum/calcium ratios were found in dialysis patients with osteomalacia vs the other types of renal osteodystrophy considered as one group. Moreover, the concentrations of several trace elements in bone were significantly correlated with each other. Bone aluminum was correlated with the time on dialysis, whereas bone iron, aluminum, magnesium, and strontium tended to be associated with patient age. Bone trace metal concentrations did not depend on vitamin D intake nor on the patients’ gender. Conclusions: The concentration of several trace elements in bone of end-stage renal failure patients is disturbed, and some of the trace metals under study might share pathways of absorption, distribution, and accumulation. The clinical significance of the increased/decreased concentrations of several trace elements other than aluminum in bone of dialysis patients deserves further investigation.

The effect of different methods of storage on the results of serum total CO2 assays

2001 ◽  
Vol 100 (6) ◽  
pp. 609-611 ◽  
Author(s):  
Matthew L. P. HOWSE ◽  
Maureen LEONARD ◽  
Michael VENNING ◽  
Laurence SOLOMAN
Keyword(s):  
Renal Failure ◽  
Metabolic Acidosis ◽  
Room Temperature ◽  
Dialysis Patients ◽  
End Stage Renal Failure ◽  
Clinically Significant ◽  
End Stage

Metabolic acidosis frequently complicates end-stage renal failure. In haemodialysis patients its severity is usually monitored by measurement of the total CO2 (TCO2) level. Samples from ‘satellite dialysis’ patients are often stored prior to analysis. We investigated the affect of storage of 21 samples for 24 h under different conditions prior to analysis. If samples were stored at room temperature the TCO2 fell from 22.7±4.2 mmol/l to 21.6±3.7 mmol/l (P = 0.001). If the same samples were spun and stored at 4 °C the TCO2 was 22.4±3.9 mmol/l (P = not significant). We conclude that the magnitude in the fall of TCO2 stored at room temperature for 24 h is unlikely to be clinically significant and can be prevented by spinning the sample and refrigerating it.

scholarly journals Glycemic index of nuggets made from eel flour (Monopterus albus) and tempeh flour for nutritional support for diabetic hemodialysis patients

2019 ◽  
Vol 3 (1) ◽  
pp. 35
Author(s):  
Fery Lusviana Widiany
Keyword(s):  
Renal Failure ◽  
Glycemic Index ◽  
Group Intervention ◽  
Nutritional Support ◽  
Hemodialysis Patients ◽  
Monopterus Albus ◽  
End Stage Renal Failure ◽  
Glucose Levels ◽  
End Stage ◽  
Low Glycemic Index

Background: Diabetes mellitus is one of the cause of end-stage renal failure and is also a comorbid of end-stage renal failure patient with hemodialysis. Diabetes is difficult to treat in diabetic hemodialysis patients. Diabetic hemodialysis patients will also experience malnutrition because of inadequate protein intake and gastrointestinal disorders such as nausea, vomiting, and anorexia, so nutritional support that meets the requirements of the diabetic hemodialysis diet is needed, which is high in protein, high in calcium, low in phosphorus, and has a low glycemic index, completed by nuggets made from a mixture of eel flour and tempeh flour. Objective: To determine the quantity and glycemic index category of nuggets made from a mixture of eel flour and tempeh flour with a proportion of 50%: 50% as nutritional support for diabetic hemodialysis patients. Methods: This experimental study using the one group intervention without control design used objects in the form of nuggets with the proportion of mixing eel flour (Monopterus albus) and tempeh flour by 50%: 50%. The measurement of glycemic index was carried out after respondents consumed test food (nuggets). Blood glucose levels measurement conducted at 30th minute, 60th minute, 90th minute, and 120th minute respectively. Results: The nugget’s glycemic index was 48.06, so it was categorized as a low glycemic index. Conclusion: Nugget made from eel flour and tempeh flour with a proportion of 50%: 50% is categorized as a food with low glycemic index, and it can be given as nutritional support for diabetic hemodialysis patients.

DOMINAN FACTORS RELATED TO QUALITY OF LIFE OF PATIENTS WITH END STAGE RENAL FAILURE UNDERGOING HEMODIALYSIS AT TABANAN GENERAL HOSPITAL

2018 ◽  
Vol 2 (2) ◽  
pp. 195
Author(s):  
Anselmus Aristo Parut ◽  
I Gusti Ayu Puja Astuti Dewi
Keyword(s):  
Quality Of Life ◽  
Renal Failure ◽  
General Hospital ◽  
Hemodialysis Patients ◽  
The Body ◽  
Dominant Factor ◽  
Life Questionnaire ◽  
End Stage Renal Failure ◽  
End Stage

Background : Renal failure is a clinical condition which irreversible reduction in renal function and need hemodialysis as replacement for kidney function. Hemodialysis is a dialysis that perform outsite the body. Indonesian Association Of Nephrology (Pernerfi) stated that new hemodialysis and active hemodialysis patients in Indonesia since 2007-2018 increased, 14.644 new hemodialysis patients and 7.276 active hemodialysis patients.Method : This is a descriptive analysis study with cross-sectional design and multiple logistic regression to identify dominant factor related to quality of life hemodialysis patients. Location of this research was Tabanan General Hospital. The sampling technique was nonprability sampling with total population were 166 patients. Data collected using insomnia questionnaire, family support questionnaire, quality if life questionnaire and complication observation form. Result : The result showed that, higher OR found in intra hemodialysis variabel (OR:180,917), which mean that intra hemodialysis complication is a dominan factor related to quality of life hemodialysis patients. Patients who had complication were more likely to have low quality of life. Further study are needed to identify factors related to intra hemodialysis complications.  Keywords : Dominan factors, intra hemodialysis complications, quality if life, end stage renal failure, hemodialysis.  

Pharmacokinetics of Recombinant Hirudin in Hemodialyzed End-stage Renal Failure Patients

1997 ◽  
Vol 77 (04) ◽  
pp. 650-655 ◽  
Author(s):  
R Vanholder ◽  
A Camez ◽  
N Veys ◽  
A Van Loo ◽  
A M Dhondt ◽  
...  
Keyword(s):  
Renal Failure ◽  
Renal Function ◽  
Residual Renal Function ◽  
Hemodialysis Patients ◽  
The Body ◽  
Pharmacokinetic Data ◽  
High Flux ◽  
Recombinant Hirudin ◽  
End Stage Renal Failure ◽  
End Stage

SummaryRecently, hirudin was used for the first time as an anticoagulant during hemodialysis in men. Pharmacokinetic data of this compound in end-stage renal failure are however not available. In this study, the pharmacokinetics of recombinant hirudin (HBW 023) was evaluated in hemodialysis-treated end-stage renal failure patients. HBW 023 was administered as a bolus at the start of a single dialysis (0.02 to 0.08 mg/kg) in 20 patients, and plasma hirudin levels were followed during this and the 5 following dialyses, without additional hirudin administration. The initial dialysis (HDj) was performed with a low flux polysulfone dialyzer; the following dialyses (up to HD6) with a high flux polysulfone dialyzer and regular heparin. Hirudin levels averaged 504.0 ± 214.0 and 527.7 ± 217.1 ng/ml in the middle and at the end of HDj, and then gradually decreased to 15.2 ± 15.2 ng/ml at the end of HD6. Pharmacokinetic data were compared to those obtained in healthy controls (n = 5), receiving the same dose, and reaching the same peak hirudin level. Hirudin half-life was >30 times longer in hemodialysis patients (51.8 ± 15.6 vs. 1.7 ± 1.5 h, p <0.001), whereas area under the curve was >60 times higher (34,669 ± 14,898 vs. 545 ± 205 ng/ml X h, p <0.001). Distribution volume was lower in hemodialysis patients (11.0 ± 3.1 vs. 14.1 ± 2.0 1, p <0.05). Hirudin disappearance rate was the same during high flux polysulfone dialysis as during interdialytic periods. Hirudin removal was markedly higher in those patients still maintaining some residual renal function and parameters of hirudin removal were significantly correlated to residual creatinine clearance. It is concluded that hirudin removal from the body is markedly depressed in hemodialyzed end-stage renal failure patients and that even minor residual renal function may increase this removal rate.

The Effect of Somatostatin on the Hormonal Abnormalities of End Stage Renal Disease

1981 ◽  
Vol 9 (1) ◽  
pp. 1-5
Author(s):  
Thomas G Murray ◽  
Carol Eisen ◽  
Morris Grabie ◽  
Ellen Buerklin ◽  
Barry R Walker ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Renal Failure ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Control Period ◽  
Thyroid Stimulating Hormone ◽  
Dialysis Patients ◽  
End Stage Renal Failure ◽  
Stage Renal Disease ◽  
End Stage

Patients with end stage renal disease who are maintained on haemodialysis have elevated levels of many hormones, some of which may play a role in the pathogenesis of the complications of uraemia. The infusion of synthetic somatostatin reduces the circulating level of many of these same hormones in patients with normal renal function. If the elevated hormone levels in dialysis patients could be similarly lowered, study of the pathogenitic significance of the various hormonal abnormalities would be facilitated. With this in mind, the effect of synthetic somatostatin on the circulating level of growth hormone, glucagon, insulin, gastrin, parathyroid hormone, and thyroid stimulating hormone in dialysis patients was investigated. In pilot protocol, a dose of 2 mg of somatostatin infused over 24, 18, or 12 hours (two patients each) was found to have no effect on any hormonal level. Infusion of 2 mg of somatostatin over 4 hours, however, was associated with consistent fall in the level of growth hormone (13.6 ± 6.2 to 6.53 ± 2.9, p = 0.15) and glucagon (595.0 ± 73 to 441 ± 28, p < 0.05) in each of four patients. The percentage change in the level of growth hormone and glucagon during the 4-hour somatostatin infusion was significantly different from the change occurring during a 4-hour timed control period (growth hormone —45 ± 18% vs +9 ± 7%, [p < 0.05]), (glucagon −27% ± 2% vs + 8 ± 2%, [p < 0.01]). There was no change in the level of any other hormone during the 4-hour infusion. No significant adverse effects were seen. This study suggests that the intravenous infusion of somatostatin can, at least on an acute basis, lower the level of growth hormone and glucagon in patients with end stage renal failure; and, therefore, it may be useful in further study and possibly the treatment of the hormonal abnormalities of end stage renal disease.

scholarly journals Short- and long-term outcomes in patients undergoing valve surgery with end-stage renal failure receiving chronic hemodialysis

2012 ◽  
Vol 144 (1) ◽  
pp. 117-123 ◽  
Author(s):  
Vinod H. Thourani ◽  
Eric L. Sarin ◽  
Patrick D. Kilgo ◽  
Omar M. Lattouf ◽  
John D. Puskas ◽  
...  
Keyword(s):  
Renal Failure ◽  
Chronic Hemodialysis ◽  
Valve Surgery ◽  
Long Term Outcomes ◽  
End Stage Renal Failure ◽  
Short And Long Term ◽  
End Stage

scholarly journals The Telemedicine applied to the follow up of patients with End Stage Renal Failure

2018 ◽  
Vol 1 (2) ◽  
pp. 51-58
Author(s):  
Pierre SIMON
Keyword(s):  
Renal Failure ◽  
Chronic Disease ◽  
Social Life ◽  
Mobile Apps ◽  
Developed Countries ◽  
Chronic Hemodialysis ◽  
End Stage Renal Failure ◽  
Hygiene Measures ◽  
End Stage ◽  
The Relationship

Abstract In the 21st century, renal failure is a chronic disease that affects several millions people in France and around 600 millions worldwide. Its prevalence in the general population increases with the lengthening of the life expectancy that characterizes the developed countries and which begins to appear in the developing countries. Chronic hemodialysis is a treatment that saved many children and young adults in the 20th century whose kidneys were destroyed by several infectious and toxic agents and by untreated malignant hypertension. These causes have been controlled by hygiene measures, anti-infective agents or protective pharmacological agents of the cardiovascular system. Today the causes of end stage renal failure are dominated by degenerative diseases due to aging, such as diabetes and chronic vascular disease. The prevention of the worsening of chronic renal failure is now possible due to better control of high blood pressure and diabetes which are the two main causes of kidney destruction. Hemodialysis treatment cannot always be relayed by renal transplantation. Many patients remain on chronic hemodialysis until they die. It is important to adapt the conditions of treatment to the social life of patients affected by this chronic disease so that these are the best possible. This is the goal of telemedicine that allows to remotely monitor the main clinical and biological factors associated with the worsening of the disease. Teledialysis (hemodialysis and peritoneal dialysis) allows to perform dialysis sessions at home or at the nearest in home substitutes (nursing home) or in satellite units of hemodialysis. Similarly, when the patient is transplanted, it makes possible to either lighten or intensify the surveillance according to the risk or not of graft rejection through home teleconsultation.The tools of the digital era such as telemedicine, health connected with connected objects and mobile apps for medical purposes, the performance of which is increasing with the algorithms of artificial intelligence (machine learning, deep learning), can improve the relationship between the patient and his doctor. An ethical reflection must be associated with all these innovations. New exercise of the medicine will be greatly enriched due to medical time more devoted to the relationship with the patient. The new care organizations made possible by digital technologies must be taught to the new generations of nephrologists.  

Sign in / Sign up

Export Citation Format

Share Document